Exagen Inc
NASDAQ:XGN

Watchlist Manager
Exagen Inc Logo
Exagen Inc
NASDAQ:XGN
Watchlist
Price: 4.06 USD -5.8%
Market Cap: $92m

Net Margin

-29.9%
Current
Improving
by 18.7%
vs 3-y average of -48.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-29.9%
=
Net Income
$-19m
/
Revenue
$63.6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-29.9%
=
Net Income
$-19m
/
Revenue
$63.6m

Peer Comparison

Country Company Market Cap Net
Margin
US
Exagen Inc
NASDAQ:XGN
91.4m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 78% of companies in the United States of America
Percentile
22nd
Based on 15 072 companies
22nd percentile
-29.9%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Exagen Inc
Glance View

Market Cap
92m USD
Industry
Biotechnology

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 219 full-time employees. The company went IPO on 2019-09-19. The firm offers physicians testing for patients and healthcare providers in diagnosis, prognosis, and monitoring of autoimmune conditions. The firm develops and commercialize testing products under the brand name AVISE. Its products include AVISE CTD, AVISE Lupus, AVISE APS, AVISE Vasculitis AAV, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE PC4d, AVISE SLE Monitor and AVISE MTX. The firm's lead testing product AVISE enables diagnosis for patients with symptoms of connective tissue diseases (CTD) and Systemic lupus erythematosus (SLE). The Company’s AVISE brand allows for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis (RA). The Company’s product portfolio integrates proprietary CB-CAPs technology, which is a stable and reliable method for differentially diagnosing systemic lupus erythematosus.

XGN Intrinsic Value
2.58 USD
Overvaluation 36%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-29.9%
=
Net Income
$-19m
/
Revenue
$63.6m
What is Exagen Inc's current Net Margin?

The current Net Margin for Exagen Inc is -29.9%, which is above its 3-year median of -48.7%.

How has Net Margin changed over time?

Over the last 3 years, Exagen Inc’s Net Margin has increased from -88.3% to -29.9%. During this period, it reached a low of -104% on Dec 31, 2022 and a high of -27.2% on Dec 31, 2024.

Back to Top